A Phase 2 interventional study of Standard Radiation Therapy and Standard Temozolomide in Glioblastoma Multiforme of Brain, sponsored by Emory University. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Emory University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Glioblastoma by Emory University — none open to participants now, 1 under way, none of them phase 3. Glioblastoma · Emory University.
Among the 12 studies in Glioblastoma by Emory University, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2014, is one of 5 in phase 2, and was the 5th registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →None of the 12 studies in Glioblastoma by Emory University is open now. The open studies under Glioblastoma, anywhere →
Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6
First in 1995; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 36 across 1,758 interventional studies indexed under Glioblastoma.
Median enrollment 12 across the 11 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.
Of its 238 completed or terminated interventional studies of FDA-regulated products, 179 (75%) have results posted.
1 of the studies in Glioblastoma by Emory University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05798507Emory UniversityIdentification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma | 2026-12-03 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Glioblastoma by Emory University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In the first phase of this study (Cohort 1), the investigators will determine the feasibility of adding MRSI to the evaluation of newly-diagnosed GBM patients treated with standard RT/TMZ and determine whether magnetic resonance spectroscopic imaging (MRSI) can predict for better outcomes in these patients. In the second phase of this study (Cohorts 2a and 2b), the investigators will find the maximum tolerated dose of belinostat for treating newly-diagnosed GBM patients with standard RT/TMZ and will determine whether MRSI can aid clinicians in the early determination of response to this new therapy.
Patients will be assigned to Cohort 1 (standard RT/TMZ) followed by entry to either Cohort 1 or Cohort 2a (standard RT/TMZ + dose finding for belinostat), followed by assignment to Cohort 2b (standard RT/TMZ + tolerable dose of belinostat).
Patients will undergo MRSI scans before beginning treatment and then at several time points during treatment to look for the early response of their tumor to treatment. Blood and tumor samples will be used to measure the levels of certain markers within the cancer cells. Patients will also be assessed for the side effects they experience. Progression-free and overall survival outcomes will be recorded. Patients will also have assessment of their depressive symptoms, quality-of-life and neurocognitive function at several time points during and after therapy course.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have the following lab values ≤ 14 days prior to registration:
Exclusion Criteria:
Taking any of the following Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes ≤ 7 days prior to registration (for cohorts 2a and 2b [belinostat cohorts] only)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Standard radiation therapy * Standard temozolomide
Radiation: Standard Radiation Therapy · Drug: Standard Temozolomide
* Standard radiation therapy * Standard temozolomide * Belinostat
Radiation: Standard Radiation Therapy · Drug: Standard Temozolomide · Drug: Belinostat
Radiation therapy to 60 Gy
Temozolomide given orally
Also known as: Temodar
Belinostat dose to be determined, given intravenously over 30-45 minutes
Also known as: Beleodaq, PXD101
Progression Free Survival (PFS)
The investigators will use a support vector machine approach to determine an MRSI 5-metabolite profile at week 3 in Cohort 1 that is predictive of prolonged PFS at 9 months.
Time frame: From date of registration to date of progression or death
Maximum Tolerated Dose of Belinostat (Cohort 2a)
The investigators will determine the maximum tolerated dose of belinostat (up to 1000 mg/day x 5 days q3weeks x 3) used with standard RT/temozolomide for newly diagnosed GBM patients.
Time frame: 9 weeks
Median Overall Survival
Overall survival was defined as the time from the date of surgery until death from any cause. Participants who were alive or lost to follow-up were censored at their last known follow-up. Median overall survival was estimated using the Kaplan-Meier method.
Time frame: From the date of surgery until death or last known follow-up; median follow-up was 50 months.
Progression Free Survival
The investigators will determine whether changes in MRSI metabolite maps at day 8 (for Cohort 2 only) and week 11 (for Cohort 1 and 2) predict for PFS at 9 months.
Time frame: From date of registration to date of progression or death
| Milestone | Std RT/TMZ (Cohort 1) | Std RT/TMZ + Belinostat (Cohorts 2a) | Std RT/TMZ + Belinostat (Cohort 2b) |
|---|---|---|---|
| Started | 14 | 4 | 10 |
| Completed | 13 | 4 | 9 |
| Not completed | 1 | 0 | 1 |
The investigators will use a support vector machine approach to determine an MRSI 5-metabolite profile at week 3 in Cohort 1 that is predictive of prolonged PFS at 9 months.
| months | Std RT/TMZ (Cohort 1) | Std RT/TMZ + Belinostat (Cohorts 2a) | Std RT/TMZ + Belinostat (Cohorts 2b) |
|---|---|---|---|
| Progression Free Survival (PFS) | 9.0 (2.9 to 45.4) | 8.4 (3.3 to 42.3) | 11.2 (3.3 to 19.3) |
The investigators will determine the maximum tolerated dose of belinostat (up to 1000 mg/day x 5 days q3weeks x 3) used with standard RT/temozolomide for newly diagnosed GBM patients.
| mg | Active Comparator: Std RT/TMZ (Cohort 1) | Std RT/TMZ + Belinostat (Cohorts 2a & 2b) |
|---|---|---|
| Maximum Tolerated Dose of Belinostat (Cohort 2a) | 0 | 500 |
Overall survival was defined as the time from the date of surgery until death from any cause. Participants who were alive or lost to follow-up were censored at their last known follow-up. Median overall survival was estimated using the Kaplan-Meier method.
| months | Std RT/TMZ (Cohort 1) | Std RT/TMZ + Belinostat (Cohorts 2a) | Std RT/TMZ + Belinostat (Cohort 2b) |
|---|---|---|---|
| Median Overall Survival | 15.8 (5.9 to 62.2) | 18.5 (7.4 to 49.3) | 20.5 (9.4 to 41.4) |
The investigators will determine whether changes in MRSI metabolite maps at day 8 (for Cohort 2 only) and week 11 (for Cohort 1 and 2) predict for PFS at 9 months.
| months | Std RT/TMZ (Cohort 1) | Std RT/TMZ + Belinostat (Cohort 2a) | Std RT/TMZ + Belinostat (Cohorts 2b) |
|---|---|---|---|
| Progression Free Survival | 9.0 (2.9 to 45.4) | 8.4 (3.3 to 42.3) | 11.2 (3.3 to 19.3) |
Collected over All-Cause Mortality was assessed through study completion, up to 6 years; all adverse events were collected through 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Std RT/TMZ (Cohort 1) | 0/13 (0%) | 0/13 (0%) | 12/13 (92.3%) |
| Std RT/TMZ + Belinostat (Cohort 2a) | 0/4 (0%) | 2/4 (50%) | 3/4 (75%) |
| Std RT/TMZ + Belinostat (Cohort 2b) | 0/9 (0%) | 6/9 (66.7%) | 2/9 (22.2%) |
| Event | Std RT/TMZ (Cohort 1) | Std RT/TMZ + Belinostat (Cohort 2a) | Std RT/TMZ + Belinostat (Cohort 2b) |
|---|---|---|---|
| ThrombocytopeniaInvestigations | 0/13 | 2/4 | 0/9 |
| HeadacheNervous system disorders | 0/13 | 0/4 | 3/9 |
| NeutropeniaInvestigations | 0/13 | 1/4 | 0/9 |
| Wound infectionInfections and infestations | 0/13 | 1/4 | 0/9 |
| SeizureNervous system disorders | 0/13 | 0/4 | 1/9 |
| AgitationPsychiatric disorders | 0/13 | 0/4 | 1/9 |
| AnxietyPsychiatric disorders | 0/13 | 0/4 | 1/9 |
| ConfusionPsychiatric disorders | 0/13 | 0/4 | 1/9 |
| PsychosisPsychiatric disorders | 0/13 | 0/4 | 1/9 |
| PalpitationsCardiac disorders | 0/13 | 0/4 | 1/9 |
| Event | Std RT/TMZ (Cohort 1) | Std RT/TMZ + Belinostat (Cohort 2a) | Std RT/TMZ + Belinostat (Cohort 2b) |
|---|---|---|---|
| AgitationPsychiatric disorders | 10/13 | 0/4 | 0/9 |
| ConfusionPsychiatric disorders | 10/13 | 1/4 | 0/9 |
| Psychiatric disordersPsychiatric disorders | 3/13 | 2/4 | 0/9 |
| InsomniaPsychiatric disorders | 5/13 | 0/4 | 2/9 |
| AnxietyPsychiatric disorders | 3/13 | 1/4 | 0/9 |
| DepressionPsychiatric disorders | 3/13 | 0/4 | 0/9 |
| Age, Categorical(Participants) | Std RT/TMZ (Cohort 1) | Std RT/TMZ + Belinostat (Cohorts 2a) | Std RT/TMZ + Belinostat (Cohorts 2b) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 4 | 7 | 21 |
| >=65 years | 3 | 0 | 2 | 5 |
| Age, Continuous(years) | Std RT/TMZ (Cohort 1) | Std RT/TMZ + Belinostat (Cohorts 2a) | Std RT/TMZ + Belinostat (Cohorts 2b) | Total |
|---|---|---|---|---|
| Mean | 58.5 ± 11.1 | 51.0 ± 5.8 | 51.3 ± 14.4 | 54.85 ± 11.4 |
| Sex: Female, Male(Participants) | Std RT/TMZ (Cohort 1) | Std RT/TMZ + Belinostat (Cohorts 2a) | Std RT/TMZ + Belinostat (Cohorts 2b) | Total |
|---|---|---|---|---|
| Female | 6 | 2 | 4 | 12 |
| Male | 7 | 2 | 5 | 14 |
| Ethnicity (NIH/OMB)(Participants) | Std RT/TMZ (Cohort 1) | Std RT/TMZ + Belinostat (Cohorts 2a) | Std RT/TMZ + Belinostat (Cohorts 2b) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 13 | 4 | 9 | 26 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Std RT/TMZ (Cohort 1) | Std RT/TMZ + Belinostat (Cohorts 2a) | Std RT/TMZ + Belinostat (Cohorts 2b) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 | 2 |
| White | 11 | 4 | 8 | 23 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Std RT/TMZ (Cohort 1) | Std RT/TMZ + Belinostat (Cohorts 2a) | Std RT/TMZ + Belinostat (Cohorts 2b) | Total |
|---|---|---|---|---|
| United States | 13 | 4 | 9 | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2014 to primary completion in Mar 2019, 58 months.
Results were first posted in Oct 2026, 7 years 7 months after primary completion.
Of 197 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's 58 months is close to that.
Counting every sponsor, half of 248 studies reached it within 55 months; a quarter within 40 and three quarters within 87.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Aug 2023 → Mar 2019 and completion Aug 2024 → Jan 2022.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belinostat